Park Medi World Limited (PARKHOSPS)
₹235.70 +0.23% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Park Medi's revenue was ₹476 Cr (+19.3% year on year, +3.4% on the previous quarter), and net profit ₹89.0 Cr (+34.8% year on year); the operating margin was 26.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹476 | +19.3% | +3.4% |
| Operating profit | ₹126 | +20.0% | -1.1% |
| Net profit | ₹89.0 | +34.8% | +15.9% |
| EPS (₹) | 1.91 | +26.5% | +7.3% |
| Operating margin | 26.5% | — | — |
PARKHOSPS delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 37.68% of the PARKHOSPS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.01%. That is lower than usual for this stock. Volume was 0.4 times its average, well below normal. It closed at a price band (circuit) on 1 session in about the last 20.
Delivery in the last 5 sessions: 60.6% · 28.5% · 42.0% · 47.1% · 37.7%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Park Medi World Limited disclosed that the Income Tax Department conducted a verification exercise at some premises of the company and select subsidiaries. The company stated that officials have cooperated with the authorities and asserted that the verification has no impact on its operational performance. With Park Medi World commanding a market cap of ₹10,087 Cr and generating TTM revenue of ₹1,756 Cr, the financial magnitude and outcome of the tax proceedings remain unquantified.
- Verification conducted by Income Tax Department at premises of Park Medi World and subsidiaries
- Company confirmed company officials cooperated with the regulatory agency
- Management states no impact on the company's operational performance
- Intimation submitted under Regulation 30 on October 14, 2026
Park Medi World Limited disclosed the voting results of its 15th Annual General Meeting held on September 22, 2026. Shareholders approved all agenda items, including the adoption of FY26 financial statements and director re-appointment. Special resolutions amending and ratifying the PARK Employee Stock Option Scheme 2025, including its extension to subsidiary and group company employees, were passed with 99.04% and 93.72% support, respectively. Total voting turnout stood at 89.96% of the 43,19,30,864 outstanding equity shares.
- Overall voter turnout stood at 89.96%, with 38,85,60,953 votes polled out of 43,19,30,864 outstanding shares
- Adoption of FY26 audited standalone and consolidated financial statements passed with 99.9999% votes in favour
- Special resolution to amend and ratify ESOP Scheme 2025 approved with 99.04% votes in favour
- Resolution extending ESOP Scheme 2025 to subsidiaries and group companies passed with 93.72% votes in favour, facing 6.28% votes against
Park Medi World Limited disclosed the voting results of its 15th Annual General Meeting held on September 22, 2026. Shareholders approved all agenda items, including the adoption of FY26 financial statements and director re-appointment. Special resolutions amending and ratifying the PARK Employee Stock Option Scheme 2025, including its extension to subsidiary and group company employees, were passed with 99.04% and 93.72% support, respectively. Total voting turnout stood at 89.96% of the 43,19,30,864 outstanding equity shares.
- Overall voter turnout stood at 89.96%, with 38,85,60,953 votes polled out of 43,19,30,864 outstanding shares
- Adoption of FY26 audited standalone and consolidated financial statements passed with 99.9999% votes in favour
- Special resolution to amend and ratify ESOP Scheme 2025 approved with 99.04% votes in favour
- Resolution extending ESOP Scheme 2025 to subsidiaries and group companies passed with 93.72% votes in favour, facing 6.28% votes against
Park Medi World Limited announced that the Park Group of Hospitals won three honours at the Healthcare Pioneers of Delhi 2026 awards on September 20, 2026. In the accompanying corporate overview, the company highlighted that it currently operates 17 hospitals with ~4,300 beds across 15 cities. It is also executing capacity additions of 2,300 beds across 6 new hospitals and 3 existing units, which will take its total network capacity to ~6,600 beds. The announcement is primarily promotional regarding awards, with previously guided expansion metrics reiterated.
- Received 3 honours at the Healthcare Pioneers of Delhi 2026 awards on September 20, 2026
- Current operational network consists of 17 hospitals with ~4,300 beds across 15 cities
- Expansion underway to add 2,300 beds across 6 incoming hospitals and 3 existing unit expansions
- Total bed capacity targeted to reach ~6,600 beds upon completion of ongoing projects
Park Medi World Limited has informed the exchanges that its management will not be participating in the Anand Rathi Annual Flagship Conference G-200 Summit 2026, which was scheduled for September 21, 2026. The company cited business exigencies for the cancellation. All other scheduled investor conferences previously disclosed on September 05, 2026, remain unchanged.
- Management will not attend the Anand Rathi Annual Flagship Conference G-200 Summit 2026 scheduled for September 21, 2026
- Cancellation is attributed to business exigencies
- Follows prior investor meet intimation dated September 05, 2026
- No changes reported to other scheduled investor conferences
Park Medi World Limited, through wholly owned subsidiary Aggarwal Hospital and Research Services Private Limited, has entered into an Operations and Management (O&M) agreement to operate a 300-bed multi-super speciality hospital in Kanpur, UP. The facility will be leased/managed under an asset-light model for a 28-year tenure, with an effective commissioning date by end of the current fiscal year (no later than April 1, 2027). Under the terms, the subsidiary will pay Axis Educational Society a revenue share of 6% with a minimum guarantee of INR 20 lakh per month. This expansion expands the group's bed capacity as it progresses toward an overall pipeline target of ~6,600 beds.
- Adds 300 beds spanning ~1.2 lakh sq. ft. in Kanpur on an asset-light O&M model
- Long-term tenure of 28 years with an effective date no later than April 1, 2027
- Commercial terms set at 6% revenue share with a minimum guarantee of INR 20 lakh per month
- Facility planned to be renovated, re-equipped, and commissioned by end of current FY
- Takes the group's operational network plus pipeline toward ~6,600 total beds across North India
Park Medi World Limited has incorporated a wholly owned subsidiary, Park Medicity Prayagraj Limited, on September 08, 2026. The entity was created to develop and operate a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh, awarded under a Public-Private Partnership (PPP) model by the Prayagraj Municipal Corporation. The initial cost of acquisition/incorporation is Rs 0.15 crore for 1,50,000 equity shares of face value Rs 10 each. This planned 550-bed addition aligns with the company's broader stated strategy to expand its operational bed capacity from 3,250 beds.
- Incorporated wholly owned subsidiary Park Medicity Prayagraj Limited on September 08, 2026
- Subscribed share capital of Rs 0.15 crore comprising 1,50,000 equity shares of Rs 10 each
- Entity will develop and operate a 550-bed multi-super-speciality hospital in Prayagraj under a PPP model
- Project awarded by the Prayagraj Municipal Corporation, Uttar Pradesh
Park Medi World Limited re-submitted its standalone financial results for the quarter ended June 30, 2026, purely to comply with the machine-readable/searchable format requirement under NSE Circular NSE/CML/2018/02. The company confirmed that there are no changes to previously reported financial figures or disclosures. Standalone revenue from operations for Q1 FY27 stood at ₹335.32 million (₹33.53 crore) with a net profit after tax of ₹10.84 million (₹1.08 crore). Notes to the results also highlight ongoing corporate actions including the acquisition of 80% of V3 Healthcare Private Limited (330-bed hospital) for approximately ₹1,770 million, completed in July 2026.
- Refiling is purely administrative to ensure machine-readable formatting per NSE circular NSE/CML/2018/02, with zero change in numbers.
- Q1 FY27 standalone revenue from operations reported at ₹335.32 million vs ₹229.69 million in Q1 FY26.
- Q1 FY27 standalone profit after tax stood at ₹10.84 million vs ₹48.97 million in Q1 FY26.
- Subsequent acquisition of 80% in V3 Healthcare Private Limited (330 beds) for ~₹1,770 million closed on July 31, 2026.
- Remaining unutilized IPO proceeds as of June 30, 2026 stood at ₹648.32 million out of ₹7,700 million total proceeds.
Park Medi World Limited has scheduled participation in four institutional investor conferences throughout September 2026. The management will attend the Kotak Healthcare Forum on September 17 and the Anand Rathi G-200 Summit on September 21 in Mumbai physically. Additionally, virtual group meetings are scheduled with Kotak Securities on September 23 and Arihant Capital's Bharat Connect Conference on September 28. No unpublished price-sensitive information is slated to be shared.
- Participating in Kotak Healthcare Forum on September 17, 2026 (Physical, 12:00 p.m. onwards in Mumbai)
- Attending Anand Rathi Annual Flagship Conference G-200 Summit on September 21, 2026 (Physical, 11:00 a.m. onwards)
- Virtual group meetings scheduled with Kotak Securities on September 23, 2026 (11:00 a.m. onwards)
- Participating in Arihant Capital Bharat Connect Conference virtually on September 28, 2026 (12:00 p.m. onwards)
Park Medi World Limited has announced the voting results of its postal ballot concluded on September 03, 2026. Shareholders approved a special resolution to amend certain objects of the company's Initial Public Offer (IPO) proceeds with 99.999% votes cast in favour. Out of 39,51,51,375 total votes polled (representing 91.48% voter turnout), 39,51,47,456 votes supported the amendment while 3,919 voted against.
- Special resolution to amend IPO objects passed with 99.999% votes in favour (39,51,47,456 shares)
- Total voter participation stood at 91.4849% of the total 43,19,30,864 paid-up equity shares
- 100% of voting institutional shares (3,70,54,428 votes) voted in favour of the resolution
- Total paid-up equity capital as of record date (July 31, 2026) was Rs 86.39 cr divided into 43.19 cr equity shares
Park Medi World Limited's Board approved the incorporation of a wholly-owned subsidiary SPV (proposed name Park Medicity Prayagraj Limited or Park Hospital Prayagraj Limited). The SPV will execute the development and operation of a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh, awarded under a Public-Private Partnership (PPP) model by the Prayagraj Municipal Corporation. The initial cash subscription is ₹0.15 crore (1.5 lakh equity shares of ₹10 face value). This project supports the company's broader expansion strategy to scale total capacity from 3,250 beds toward 5,260 beds.
- Incorporation of a 100% wholly-owned subsidiary SPV approved by the Board
- SPV dedicated to the development and operation of a 550-bed multi-super-speciality hospital at Prayagraj, UP
- Project awarded under Public-Private Partnership (PPP) model by Prayagraj Municipal Corporation
- Initial cash consideration of ₹0.15 crore for 1,50,000 equity shares of ₹10 each
Park Medi World has approved the incorporation of a wholly-owned subsidiary (SPV) with an initial capital of INR 0.15 crore (1,50,000 shares of Rs 10 each). The SPV will develop and operate a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh, awarded under a Public-Private Partnership (PPP) model by the Prayagraj Municipal Corporation. This project adds ~16.9% capacity to the company's existing base of 3,250 beds, advancing its target to reach 5,260 beds by March 2028.
- Board approved incorporation of a wholly-owned subsidiary for the Prayagraj project
- SPV will develop and operate a 550-bed multi-super-speciality hospital under PPP model
- Initial equity subscription cost is INR 0.15 crore (1,50,000 shares at Rs 10 each)
- Represents a ~16.9% addition to the company's current operational capacity of 3,250 beds
Park Medi World Limited has announced that its 15th Annual General Meeting (AGM) will be held via Video Conferencing on Tuesday, September 22, 2026, at 11:00 a.m. IST. The company has initiated the dispatch of letters containing web links to the FY 2025-26 Annual Report and AGM Notice for shareholders without registered emails as of August 21, 2026. The remote e-voting cut-off date is set for September 15, 2026, with the voting window open from September 18 to September 21, 2026.
- 15th AGM scheduled for Tuesday, September 22, 2026, at 11:00 AM IST via Video Conferencing
- Remote e-voting period runs from September 18, 2026 (09:00 AM IST) to September 21, 2026 (05:00 PM IST)
- Cut-off date for remote e-voting eligibility determined as Tuesday, September 15, 2026
- Shareholder record cut-off for initial email list dispatch was August 21, 2026
Park Medi World Limited has released its FY25-26 Annual Report and scheduled its 15th Annual General Meeting for September 22, 2026. For FY26, the company reported revenue of ₹1,679.4 Cr (up 21% YoY), EBITDA of ₹444.3 Cr (margin of 26.5%), and PAT of ₹273.6 Cr (up 27% YoY). The group operated at 64% average occupancy with an ARPOB of ₹28,005 and bed capacity reaching 3,610 beds as of March 31, 2026. Remote e-voting for the AGM is scheduled from September 18 to September 21, 2026, with a cut-off date of September 15, 2026.
- FY26 Revenue from operations stood at ₹16,794 Mn (₹1,679.4 Cr), reflecting a 21% YoY growth.
- FY26 EBITDA reached ₹4,443 Mn with a 26.5% EBITDA margin, while PAT grew 27% YoY to ₹2,736 Mn.
- Total bed capacity increased by 20% YoY to 3,610 beds as of March 31, 2026, operating at 64% average occupancy and ₹28,005 ARPOB.
- AGM scheduled for September 22, 2026, with remote e-voting open between September 18 and September 21, 2026.
Park Medi World Limited has secured a Public-Private Partnership (PPP) mandate from Prayagraj Municipal Corporation to construct and operate a 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh. The project requires an estimated investment of ~₹200 crore over a 2-year construction period, funded via internal accruals. The State Government will reimburse ₹76.52 crore (~38% of capex), de-risking the capital outlay. Under the 45-year concession, the company will pay an annual concession fee of ₹18.10 crore with a 3% annual escalation.
- Awarded PPP concession to build and operate a 550-bed hospital in Prayagraj over a 45-year lease period
- Total project investment estimated at ~₹200 crore to be completed within 2 years from the appointed date
- Government support includes ₹76.52 crore reimbursement towards construction, de-risking ~38% of capex
- Annual concession fee payable is ₹18.10 crore with an annual escalation of 3%
- Expands the group's Uttar Pradesh footprint to 1,260 beds and total network pipeline toward ~6,300 beds
Financial Performance
Revenue Growth by Segment
Total operating income grew 13.16% YoY to INR 1,393 Cr in fiscal 2025 from INR 1,231 Cr in fiscal 2024. Revenue is well-diversified across specialties, with no single specialty accounting for more than 16% of total revenue in fiscal 2025.
Geographic Revenue Split
100% of revenue is generated from North India, with a presence in key cities including Delhi, Gurgaon, Noida, Mohali, Jaipur, Behror, Faridabad, Panipat, Karnal, Sonipat, Ambala, Patiala, and Bathinda.
Profitability Margins
Operating margins declined from 31% in fiscal 2023 to 26.8% in fiscal 2025 due to moderate occupancy in recently acquired hospitals. Reported PAT margin improved from 12.14% in fiscal 2024 to 15.45% in fiscal 2025.
EBITDA Margin
Operating margin stood at 26.8% in fiscal 2025, a decrease from 31% in fiscal 2023. This decline is attributed to the low absorption of fixed costs in new acquisitions in Patiala and Mohali and changes in accounting to IND AS.
Capital Expenditure
Planned capital expenditure of INR 150-200 Cr for fiscal 2026 to fund greenfield projects in Panchkula and brownfield expansions in Narela and Kanpur.
Credit Rating & Borrowing
Credit rating reaffirmed at 'Crisil A+/Stable' in November 2025. Sanctioned bank limits of INR 362 Cr were utilized at 25% on average through June 2025.
Operational Drivers
Raw Materials
Medical consumables, surgical implants, and pharmaceutical drugs (specific % of total cost not disclosed).
Capacity Expansion
Current capacity of 3,250 beds across 14 hospitals; planned expansion to reach 5,260 beds by March 2028 through the addition of 2,010 beds via 7 hospitals under execution.
Manufacturing Efficiency
Average Revenue Per Occupied Bed (ARPOB) is healthy at approximately INR 26,000. Occupancy levels in recently acquired units remain a key monitorable for efficiency.
Strategic Growth
Expected Growth Rate
22%
Growth Strategy
Growth will be achieved through a cluster-based model, expanding bed capacity from 3,250 to 5,260 by March 2028. This includes integrating 7 hospitals currently under execution and acquiring brownfield projects like the 250-bed Krishna Super-speciality Hospital for INR 40 Cr. Growth is also driven by improving occupancy in recently acquired units in Patiala and Mohali and maintaining a healthy ARPOB of INR 26,000.
Products & Services
Super-specialty clinical services including Cardiology, Neurology, Oncology, Orthopaedics, Gastroenterology, Critical Care, Nephrology, and Women & Child Health.
Brand Portfolio
Park Group of Hospitals, Park Medi World.
New Products/Services
Integration of 7 new hospitals adding 2,010 beds by 2028; acquisition of Krishna Super-speciality Hospital (250 beds) in Bathinda.
Market Expansion
Targeting North India regions including Panchkula, Narela, and Kanpur with a timeline to reach 5,260 beds by March 2028.
Market Share & Ranking
Ranked as North India’s 2nd largest hospital chain.
External Factors
Industry Trends
The North Indian healthcare market is shifting towards large multi-specialty chains that can offer metropolitan-grade care in regional hubs. Park Group is positioning itself to capture this by expanding into cities like Bathinda and Panchkula, leveraging technology-enabled ecosystems to improve clinical outcomes.
Competitive Landscape
Operates as the 2nd largest chain in North India, competing with other multi-specialty providers in the Delhi-NCR and Punjab regions.
Competitive Moat
The group's moat is its 30-year brand recall and the promoters' proven ability to turn brownfield acquisitions profitable quickly. This is sustainable because high capital intensity and specialized talent requirements create significant entry barriers, while the group's established presence in 14 locations provides a strong referral network.
Consumer Behavior
Increasing consumer demand for metropolitan-grade healthcare locally in regional and rural districts like Bathinda and Patiala.
Regulatory & Governance
Industry Regulations
Operations are governed by medical waste pollution norms, healthcare facility standards, and pricing regulations on essential medical supplies. Compliance is critical to avoid operational disruptions in its 14 multi-specialty hospitals.
Risk Analysis
Key Uncertainties
The primary risk is the timely stabilization of the 2,010 new beds planned by 2028. If occupancy remains moderate, the operating margin could fall below 23%, which would reduce cash accruals below the expected INR 300-320 Cr level.
Geographic Concentration Risk
100% of revenue is derived from North India (Delhi, Haryana, Punjab, Rajasthan), making the group sensitive to regional economic shifts or regulatory changes in these specific states.
Technology Obsolescence Risk
The group is mitigating technology risks by investing in modern medical infrastructure, including modular OTs and automated laboratories, to ensure clinical excellence and maintain its INR 26,000 ARPOB.
